[1]
|
Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J. and Jemal, A. (2015) Global Cancer Statistics, 2012. CA: A Cancer Journal for Clinicians, 65, 87-108.
https://doi.org/10.3322/caac.21262
|
[2]
|
O’Shaughnessy, J. (2005) Extending Survival with Chemotherapy in Metastatic Breast Cancer. The Oncologist, 10, 20-29.
https://doi.org/10.1634/theoncologist.10-90003-20
|
[3]
|
Metastatic Breast Cancer Network (2016) Incidence and Incidence Rates.
http://www.mbcn.org/incidence-and-incidence-rates/
|
[4]
|
Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., Andre, F., et al. (2014) ESO-ESMO 2nd International Consensus Guidelines for Advanced Breast Cancer (ABC2) Dagger. Annals of Oncology, 25, 1871-1888.
https://doi.org/10.1093/annonc/mdu385
|
[5]
|
Gradishar, W.J., Anderson, B.O., Balassanian, R., Blair, S.L., Burstein, H.J., Cyr, A., et al. (2017) NCCN Guidelines Insights: Breast Cancer, Version 1.2017. Journal of the National Comprehensive Cancer Network: JNCCN, 15, 433-451.
https://doi.org/10.6004/jnccn.2017.0044
|
[6]
|
Di Leo, A., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I.N., Khasanov, R., et al. (2010) Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg with Fulvestrant 500 mg in Postmenopausal Women with Estrogen Receptor-Positive Advanced Breast Cancer. Journal of Clinical Oncology, 28, 4594-4600. https://doi.org/10.1200/JCO.2010.28.8415
|
[7]
|
Yardley, D.A., Noguchi, S., Pritchard, K.I., Burris III, H.A., Baselga, J., Gnant, M., et al. (2013) Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis. Advances in therapy, 30, 870-884. https://doi.org/10.1007/s12325-013-0060-1
|
[8]
|
Finn, R.S., Crown, J.P., Lang, I., Boer, K., Bondarenko, I.M., Kulyk, S.O., et al. (2015) The Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib in Combination with Letrozole Versus Letrozole Alone as First-Line Treatment of Oestrogen Receptor-Positive, HER2-Negative, Advanced Breast Cancer (PALOMA-1/TRIO-18): A Randomised Phase 2 Study. The Lancet Oncology, 16, 25-35.
https://doi.org/10.1016/S1470-2045(14)71159-3
|
[9]
|
Montagna, E., Cancello, G., Dellapasqua, S., Munzone, E. and Colleoni, M. (2014) Metronomic Therapy and Breast Cancer: A Systematic Review. Cancer Treatment Reviews, 40, 942-950. https://doi.org/10.1016/j.ctrv.2014.06.002
|
[10]
|
Hug, V.H.G., Drewinko, B. and Finders, M. (1985) Tamoxifen-Citrate Counteracts the Antitumor Effects of Cytotoxic Drugs in Vitro. Journal of Clinical Oncology, 3, 1672-1677. https://doi.org/10.1200/JCO.1985.3.12.1672
|
[11]
|
Albain, K.S., Barlow, W.E., Ravdin, P.M., Farrar, W.B., Burton, G.V., Ketchel, S.J., et al. (2009) Adjuvant Chemotherapy and Timing of Tamoxifen in Postmenopausal Patients with Endocrine-Responsive, Node-Positive Breast Cancer: A Phase 3, Open-Label, Randomised Controlled Trial. The Lancet, 374, 2055-2063.
https://doi.org/10.1016/S0140-6736(09)61523-3
|
[12]
|
Pico, C., Martin, M., Jara, C., Barnadas, A., Pelegri, A., Balil, A., et al. (2004) Epirubicin-Cyclophosphamide Adjuvant Chemotherapy plus Tamoxifen Administered Concurrently versus Sequentially: Randomized Phase III Trial in Postmenopausal Node-Positive Breast Cancer Patients. A GEICAM 9401 Study. Annals of Oncology, 15, 79-87. https://doi.org/10.1093/annonc/mdh016
|
[13]
|
Sui, M.H., Jiang, D.H., Hinsch, C. and Fan, W.M. (2010) Fulvestrant (ICI 182,780) Sensitizes Breast Cancer Cells Expressing Estrogen Receptor Alpha to Vinblastine and Vinorelbine. Breast Cancer Research and Treatment, 121, 335-345.
https://doi.org/10.1007/s10549-009-0472-4
|
[14]
|
Ikeda, H., Taira, N., Nogami, T., Shien, K., Okada, M., Shien, T., et al. (2011) Combination Treatment with Fulvestrant and Various Cytotoxic Agents (Doxorubicin, Paclitaxel, Docetaxel, Vinorelbine, and 5-Fluorouracil) Has a Synergistic Effect in Estrogen Receptor-Positive Breast Cancer. Cancer Science, 102, 2038-2042.
https://doi.org/10.1111/j.1349-7006.2011.02050.x
|
[15]
|
Kataoka, M., Yamaguchi, Y., Moriya, Y., Sawada, N., Yasuno, H., Kondoh, K., et al. (2012) Antitumor Activity of Chemoendocrine Therapy in Premenopausal and Postmenopausal Models with Human Breast Cancer Xenografts. Oncology Reports, 27, 303-310. https://doi.org/10.3892/or.2011.1541
|
[16]
|
de la Haba-Rodriguez, J., Mancha, R.G., Manga, G.P., Aguilar, E.A., Baena Canada, J.M., Rovira, P.S., et al. (2010) Exemestane and Chemotherapy as First-Line Treatment of Metastatic Breast Cancer: Results of a Phase II Study. Clinical Breast Cancer, 10, 313-317. https://doi.org/10.3816/CBC.2010.n.041
|
[17]
|
Aurilio, G., Munzone, E., Botteri, E., Sciandivasci, A., Adamoli, L., Minchella, I., et al. (2012) Oral Metronomic Cyclophosphamide and Methotrexate plus Fulvestrant in Advanced Breast Cancer Patients: A Mono-Institutional Case-Cohort Report. The Breast Journal, 18, 470-474. https://doi.org/10.1111/j.1524-4741.2012.01278.x
|
[18]
|
Schwartzberg, L.S., Wang, G., Somer, B.G., Blakely, L.J., Wheeler, B.M., Walker, M.S., et al. (2014) Phase II Trial of Fulvestrant with Metronomic Capecitabine for Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Clinical Breast Cancer, 14, 13-19.
https://doi.org/10.1016/j.clbc.2013.09.003
|
[19]
|
Eisenhauer, E.A., Therasse, P., Bogaerts, J., Schwartz, L.H., Sargent, D., Ford, R., et al. (2009) New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1). European Journal of Cancer, 45, 228-247.
https://doi.org/10.1016/j.ejca.2008.10.026
|
[20]
|
Bonneterre, J., Thurlimann, B., Robertson, J.F., Krzakowski, M., Mauriac, L., Koralewski, P., et al. (2000) Anastrozole versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. Journal of Clinical Oncology, 18, 3748-3757. https://doi.org/10.1200/JCO.2000.18.22.3748
|
[21]
|
Mouridsen, H., Gershanovich, M., Sun, Y., Perez-Carrion, R., Boni, C., Monnier, A., et al. (2003) Phase III Study of Letrozole versus Tamoxifen as First-Line Therapy of Advanced Breast Cancer in Postmenopausal Women: Analysis of Survival and Update of Efficacy from the International Letrozole Breast Cancer Group. Journal of Clinical Oncology, 21, 2101-2109. https://doi.org/10.1200/JCO.2003.04.194
|
[22]
|
Paridaens, R.J., Dirix, L.Y., Beex, L.V., Nooij, M., Cameron, D.A., Cufer, T., et al. (2008) Phase III Study Comparing Exemestane with Tamoxifen as First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. Journal of Clinical Oncology, 26, 4883-4890.
https://doi.org/10.1200/JCO.2007.14.4659
|
[23]
|
Ellis, M.J., Llombart-Cussac, A., Feltl, D., Dewar, J.A., Jasiowka, M., Hewson, N., et al. (2015) Fulvestrant 500 mg versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis from the Phase II FIRST Study. Journal of Clinical Oncology, 33, 3781-3787.
https://doi.org/10.1200/JCO.2015.61.5831
|
[24]
|
Robertson, J.F.R., Bondarenko, I.M., Trishkina, E., Dvorkin, M., Panasci, L., Manikhas, A., et al. (2016) Fulvestrant 500 mg versus Anastrozole 1 mg for Hormone Receptor-Positive Advanced Breast Cancer (FALCON): An International, Randomised, Double-Blind, Phase 3 Trial. The Lancet, 388, 2997-3005.
https://doi.org/10.1016/S0140-6736(16)32389-3
|
[25]
|
Ali, S. and Coombes, R.C. (2002) Endocrine-Responsive Breast Cancer and Strategies for Combating Resistance. Nature Reviews Cancer, 2, 101-112.
https://doi.org/10.1038/nrc721
|
[26]
|
Osborne, C.K., Kitten, L. and Arteaga, C.L. (1989) Antagonism of Chemotherapy-Induced Cytotoxicity for Human Breast Cancer Cells by Antiestrogens. Journal of Clinical Oncology, 7, 710-717.
|
[27]
|
Kurebayashi, J., Nukatsuka, M., Sonoo, H., Uchida, J. and Kiniwa, M. (2010) Preclinical Rationale for Combined Use of Endocrine Therapy and 5-Fluorouracil But Neither Doxorubicin Nor Paclitaxel in the Treatment of Endocrine-Responsive Breast Cancer. Cancer Chemotherapy and Pharmacology, 65, 219-225.
https://doi.org/10.1007/s00280-009-1024-7
|
[28]
|
Goldenberg, G.J. and Froese, E.K. (1985) Antagonism of the Cytocidal Activity and Uptake of Melphalan by Tamoxifen in Human Breast Cancer Cells in Vitro. Biochemical Pharmacology, 34, 763-770.
https://doi.org/10.1016/0006-2952(85)90755-5
|
[29]
|
Nukatsuka, M., Saito, H., Nakagawa, F., Abe, M., Uchida, J., Shibata, J., et al. (2011) Oral Fluoropyrimidine May Augment the Efficacy of Aromatase Inhibitor via the Down-Regulation of Estrogen Receptor in Estrogen-Responsive Breast Cancer Xenografts. Breast Cancer Research and Treatment, 128, 381-390.
https://doi.org/10.1007/s10549-010-1141-3
|
[30]
|
Rivkin, S.E., Green, S., Metch, B., Cruz, A.B., Abeloff, M.D., Jewell, W.R., et al. (1994) Adjuvant CMFVP versus Tamoxifen versus Concurrent CMFVP and Tamoxifen for Postmenopausal, Node-Positive, and Estrogen Receptor-Positive Breast Cancer Patients: A Southwest Oncology Group Study. Journal of Clinical Oncology, 12, 2078-2085. https://doi.org/10.1200/JCO.1994.12.10.2078
|
[31]
|
Bottini, A., Generali, D., Brizzi, M.P., Fox, S.B., Bersiga, A., Bonardi, S., et al. (2006) Randomized Phase II Trial of Letrozole and Letrozole plus Low-Dose Metronomic Oral Cyclophosphamide as Primary Systemic Treatment in Elderly Breast Cancer Patients. Journal of Clinical Oncology, 24, 3623-3628.
https://doi.org/10.1200/JCO.2005.04.5773
|
[32]
|
Anders, C.K., Hsu, D.S., Broadwater, G., Acharya, C.R., Foekens, J.A., Zhang, Y., et al. (2008) Young Age at Diagnosis Correlates with Worse Prognosis and Defines a Subset of Breast Cancers with Shared Patterns of Gene Expression. Journal of Clinical Oncology, 26, 3324-3330. https://doi.org/10.1200/JCO.2007.14.2471
|
[33]
|
Chang, J., Clark, G.M., Allred, D.C., Mohsin, S., Chamness, G. and Elledge, R.M. (2003) Survival of Patients with Metastatic Breast Carcinoma: Importance of Prognostic Markers of the Primary Tumor. Cancer, 97, 545-553.
https://doi.org/10.1002/cncr.11083
|
[34]
|
Lonning, P.E., Bajetta, E., Murray, R., Tubiana-Hulin, M., Eisenberg, P.D., Mickiewicz, E., et al. (2000) Activity of Exemestane in Metastatic Breast Cancer after Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial. Journal of Clinical Oncology, 18, 2234-2244. https://doi.org/10.1200/JCO.2000.18.11.2234
|